 |
1 Product |  |
15 Diseases | | 1 Product |
|
0 Trials |  |
6 News |  |
- | IMF-001 / ImmunoFrontier
Journal: Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy. (Pubmed Central) - Oct 1, 2022
These results suggest that PIGR would play a major role in tumor immunity in an antigen-specific manner during NY-ESO-1 vaccinations. The IgA response may be relevant.
- || Hiltonol (poly-ICLC) / Oncovir, IMF-001 / ImmunoFrontier
Clinical, Journal: Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. (Pubmed Central) - Oct 20, 2021
In a mouse model, adding anti-PD-1 antibody to the combination of CHP-NY-ESO-1/poly-ICLC suppressed the growth of NY-ESO-1-expressing tumors. Combining the vaccine with PD-1 blockade holds promise in human trials.
- | IMF-001 / ImmunoFrontier
Trial completion, Enrollment change, Trial primary completion date: Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 (clinicaltrials.gov) - Mar 10, 2015
P1, N=23, Completed, Sponsor: ImmunoFrontier, Inc.
Combining the vaccine with PD-1 blockade holds promise in human trials. Active, not recruiting --> Completed | N=15 --> 23 | Trial primary completion date: Aug 2013 --> Nov 2013
- IMF-001 / ImmunoFrontier
Enrollment change: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer (clinicaltrials.gov) - Apr 15, 2013
P1, N=25, Completed, Sponsor: ImmunoFrontier, Inc.
Active, not recruiting --> Completed | N=15 --> 23 | Trial primary completion date: Aug 2013 --> Nov 2013 N=20 --> 25
- | IMF-001 / ImmunoFrontier
Trial completion: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer (clinicaltrials.gov) - Apr 15, 2013
P1, N=25, Completed, Sponsor: ImmunoFrontier, Inc.
N=20 --> 25 Active, not recruiting --> Completed
- IMF-001 / ImmunoFrontier
Enrollment closed: Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 (clinicaltrials.gov) - Nov 26, 2012
P1, N=15, Active, not recruiting, Sponsor: ImmunoFrontier, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting